

LeenLife Pharma International Inc.

Suite 380 - 580 Hornby Street
Vancouver, B.C., V6C 3B6



NEWS RELEASE

LeenLife Pharma International:

- **Production and Operations in North America**
- **Exclusivity Agreement with BioCube™**

October 17, 2017

CSE - LLP

The Company is pleased to announce it has entered into an exclusive agreement with BioCube Corporation Ltd. ("BioCube"), an Australian company with offices in British Columbia, to purchase equipment to manufacture the Company's Omega 3 products based on flax seed oil.

BioCube, offers LeenLife Pharma a on or off-grid platform that provides seamless integration into the commercial production process of LeenLife Pharma's proprietary and industry leading Omega-3 formulations.

BioCube has developed a proprietary processing plant, having intellectual property including patents, patent applications and proprietary information and technical information (the "BioCube Processor"). The Company has identified a use for the BioCube Processor along with proprietary technology of its own to process flaxseed oil to produce its Omega 3 products. BioCube has agreed to manufacture the BioCube Processor for flaxseed oil exclusively for the Company on following terms, subject to approval by the Canadian Securities Exchange:

1. Advance payment of fixed fee to BioCube as an annual minimum royalty to be applied against a royalty of 2% of net sales of products produced using the BioCube Processor. The Company has the option to purchase one-half of the royalty for consideration of one million dollars.
2. Issuance of one million shares of the Company's stock to BioCube of which 50% will vest after one year and 50% will vest after two years.
3. The term of the agreement is 5 years with renewals of 5-year periods.

The Company is totally satisfied that the efficiency of the BioCube and the BioCube process will address concerns of food grade quality control, cost, production quotas and handling. The Company is planning to set up operations in the Vancouver area to produce and market its products in North America.

LeenLife Pharma International Inc.

Suite 380 - 580 Hornby Street
Vancouver, B.C., V6C 3B6



NEWS RELEASE

About the Company and the Market:

LeenLife products are extracted from flax seeds, a plentiful grain, an organic and a non-animal source. The products can be used as a food additive or as a nutraceutical and have been used in making bread, noodles, cheese, yogurt, juice and milk products for the European market. Their industry leading Omega 3 product formulations are of the highest quality with no cholesterol and toxic substances and are offered as an oil, emulsion and powder.

The global Omega 3 market was valued at 10 billion USD in 2016 and is expected to reach 16 billion USD by the end of 2023, growing at a CAGR of 7.57% between 2016 and 2023.

For more information, please contact:

Stan Lis, CEO

Tel: 604 764-0518

E-mail: slis@leenlifepharma.com

Forward-looking Information

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including statements that address the Transaction and the meeting of shareholders and those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs and the ability to achieve goals.